Tyr651

Site Information
NPDLVRAyGPGLEks SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 34607087
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:	lung cancer ( 2 , 3 , 4 ) , non-small cell lung cancer ( 3 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 ) , non-small cell squamous cell lung carcinoma ( 2 , 5 )
Relevant cell line - cell type - tissue:	Cal-12T (pulmonary) ( 4 ) , DMS153 (pulmonary) ( 3 ) , HCC15 (pulmonary) ( 2 ) , HCC44 (pulmonary) ( 4 ) , HeLa (cervical) ( 1 ) , LOU-NH91 (squamous) ( 2 ) , lung ( 2 , 3 , 4 ) , NCI-H1437 (pulmonary) ( 3 , 4 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H1703 (squamous) ( 2 , 5 ) , NCI-H2073 (pulmonary) ( 2 , 3 ) , NCI-H209 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 2 ) , NCI-H2405 (pulmonary) ( 4 ) , NCI-H838 (pulmonary) ( 3 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K (2012) CST Curation Set: 16139; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
6	Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
7	Possemato A (2012) CST Curation Set: 13559; Year: 2012; Biosample/Treatment: cell line, mixTMT(A549,H3255,MKN45,H3122,,H1703,H1650)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info